Project Grant W81XWH2210205

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $624,001 to New York University School of Medicine to develop a new class of compounds called multivalent peptoid conjugates (MPCs) that can antagonize the androgen receptor (AR) in prostate cancer cells. The project aims to demonstrate that these novel MPC compounds can stop the growth of prostate cancer cells that have become resistant to standard anti-androgen treatments....

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will provide $606,869 to Case Western Reserve University from July 2024 through June 2029 to study the mechanisms of androgen receptor inverse agonists in treating advanced prostate cancer. The research aims to map the epigenetic mechanisms driving treatment-resistant metastatic castration-resistant prostate cancer, and to develop novel small molecule therapies that can functionally...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The National Cancer Institute (NCI) awarded a 5-year, $371,719 Project Grant under the federal Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant supports research aimed at characterizing epigenetic targets, specifically the histone methyltransferase NSD2, and their role in regulating the oncogenic androgen receptor (AR) transcriptional program in...

This federal Project Grant award in the amount of $535,334.00 was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program. The grant supports a research project led by Albert Einstein College of Medicine to investigate the non-autonomous role of androgen signaling in prostate cancer tumorigenesis. The key focus of the project is to study how androgen receptor (AR) signaling in prostatic stromal cells, specifically those expressing the GLI1...

This federal Project Grant award, with ID R01CA285526, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $549,357 award supports research by The Washington University in St. Louis to investigate the regulation of the androgen receptor (AR) by a long non-coding RNA called NXTAR in prostate cancer. The key objectives are to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, develop PSMA-targeted...

This federal Project Grant award of $571,271 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research team at the University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in...

This National Cancer Institute project grant of $808,336 provides funding from September 2022 through August 2025 to investigate the effects of androgen receptor antagonism on human T cell function. The University of Portland will determine how androgen deprivation therapies used in prostate cancer treatment impact the adaptive immune response. Researchers will study the impact of the clinically relevant androgen receptor antagonist enzalutamide on T cells isolated from healthy volunteers in...